NEW YORK, Dec. 1 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. (GBI) - and Experigen Management Company (Experigen) announced today that Dr. Ivan Labat has joined GBI’s restructuring team to develop and manage the Company’s information systems and to provide advanced bioinformatics analysis capabilities to GBI and Biomedical Diagnostics, Inc. (Biomedical), GBI’s breast cancer diagnostic portfolio company.
Dr. Labat has been published in several peer reviewed scientific journals and is co-inventor on 42 patents. He received his doctorate degrees in Molecular Biology and Physiology from the University of Belgrade and has extensive experience in gene and protein database development and analysis, sequence analysis, drug target discovery, and experience in developing and maintaining corporate and division information systems infrastructure. He brings key experience from publicly traded biopharmaceutical companies to GBI for advanced analysis and understanding of complex and extensive gene and protein assets.
“As the scientific founder of Hyseq (now Nuvelo), Dr. Labat was substantially responsible for designing and implementing the information systems infrastructure at Hyseq that enabled their successful public offering at the highest valuation of all biotechnology companies that went public that year,” said Douglas C. Lane of Experigen. “I personally worked with Dr. Labat while I was Vice President of Corporate Development at Hyseq and I know him to be an extraordinary scientist and one of the most capable and dedicated professionals I’ve had the pleasure to work with.”
“Under Dr. Labat’s leadership, we expect Biomedical will be able to advance its mammastatin protein diagnostic business and establish a recombinant protein form of mammastatin for use in developing breast cancer diagnostic test kits and potential therapeutic applications,” said Greg McCartney, CEO of GBI. “We are very pleased Ivan has decided to join us to lead the Company in critical areas of expanding our business opportunities.”
About Experigen
Experigen is a management company retained by Genesis Bioventures, Inc. to develop and advance GBI’s investment portfolio, financing and operations.
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases.
Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com, www.gnsbio.com Experigen: (310) 443-4100, info@experigen.com, www.experigen.com Aurelius Consulting Group: (800) 644-6297, info@runonideas.com, www.runonideas.com
Genesis Bioventures, Inc.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com,www.gnsbio.com; Experigen: (310) 443-4100, info@experigen.com,www.experigen.com; Aurelius Consulting Group: (800) 644-6297,info@runonideas.com, www.runonideas.com
